Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Exclusion Criteria

• •1. Known presence of the T315I mutation at any time prior to study entry
• •2. Known second chronic phase of CML after previous progression to AP/BC
• •3. Previous treatment with a hematopoietic stem cell transplantation
• •4. Participants planning to undergo allogeneic hematopoietic stem cell transplantation
• •5. Cardiac or cardiac repolarization abnormality, including any of the following:
• •History within 6 months prior to starting study treatment of myocardial infarction, angina pectoris, coronary artery bypass graft Clinically significant cardiac arrhythmias , complete left bundle branch block, high-grade AV block QTcF at screening ≥450 msec (male participants), ≥460 msec (female participants)
• •Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
• •Risk factors for Torsades de Pointes including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia Concomitant medication(s) with a "Known risk of Torsades de Pointes" that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
• •Inability to determine the QTcF interval
• •6. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis